MaureenBennett

Partner

Boston + 1.617.449.6884 San Francisco + 1.415.875.5772

Maureen Bennett represents life sciences and health care clients conducting global clinical trials and research collaborations. For almost 20 years, Maureen has advised clients on the contractual, regulatory, and ethical issues associated with clinical research. She negotiates clinical trial agreements, reviews informed consents, provides advice regarding novel patient recruitment strategies, and assists with interactions with regulatory agencies, including the FDA. Maureen also advises clients on emerging regulatory issues affecting clinical research, including the utilization of social media in patient and physician recruitment, the development of virtual clinical trial and telemedicine networks, and personalized medicine strategies implementing the use of biomarkers and companion diagnostics.

Maureen also represents clients in the structuring of complex outsourcing arrangements between life sciences companies and contract research organizations (CROs). Maureen has recently assisted a pharmaceutical company in the negotiation of a master services agreement with a CRO for a Phase 3 clinical trial with more than 100 sites on four continents. She also represents clients in the assessment and mitigation of regulatory risks and the negotiation of liability allocation arrangements in M&A, licensing, and other commercial transactions.

Maureen is the Life Sciences co-leader for the Firm's Health Care & Life Sciences Practice and is currently serving as co-chair of the Boston Bar Association's Health Care Section. She was honorary co-chair for the 8th Annual Boston-Northwest Ireland Golden Bridges Giant Step Conference 2015 and is a regular speaker at industry conferences. Maureen is a member of the Firm's LGBTQ affinity group.

Experience

  • STERIS acquires Key Surgical for approximately $850 millionJones Day advised STERIS plc (NYSE: STE) in the $850 million acquisition of Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products, and a portfolio company of Water Street Healthcare Partners, LLC.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day is advising Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Astellas Pharma acquires iota BiosciencesJones Day advised Astellas Pharma Inc. in its acquisition of iota Biosciences.
  • Riverside portfolio company acquires INVIVO CommunicationsJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Red Nucleus of INVIVO Communications, a Toronto-based digital scientific communications provider strategically focused on the medical affairs space.
  • PolyOne acquires Clariant color and additive masterbatch business for $1.5 billionJones Day advised PolyOne Corporation in the $1.5 billion purchase of Clariant’s global color and additive masterbatch business.
  • Health care system and research institute successfully resolves national investigationJones Day represented a health care system and its research institute in a national investigation being conducted by the National Institutes of Health ("NIH") as part of its initiative investigating possible foreign influences on U.S. funded and conducted research, including research funded by NIH.
  • GM partners with Ventec to manufacture ventilators in response to coronavirus pandemicJones Day is advising General Motors Company on the "Project V" partnership with Ventec Life Systems Inc. to mass produce ventilators needed to battle the coronavirus pandemic.
  • Medical equipment company responds to U.S. federal RFI, develops global strategy for responding to requests for specialized medical equipment in response to COVID-19 pandemicJones Day advised a medical equipment company in their response to a U.S. federal RFI for specialized medical equipment in response to the COVID-19 pandemic, in development of a global strategy regarding response to multiple state and country requests for specialized medical equipment, and in related antitrust and regulatory issues.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • Cortec Group sells WU Holdco to The Carlyle Group and TA AssociatesJones Day advised the Cortec Group in the sale of WU Holdco, Inc., the holding company for Weiman Products, LLC and Urnex Brands, LLC, which are leading developers, manufacturers, and distributors of specialty cleaning products for the consumer and commercial markets, to The Carlyle Group and TA Associates.
  • KeyBank and KeyBanc Capital Markets provide $235 million credit facility to ATI Merger Sub, Avalign Holdings, and Avalign TechnologiesJones Day represented KeyBank National Association as administrative agent, collateral agent, documentation agent, issuing lender, and swing line lender, and KeyBanc Capital Markets Inc., as joint lead arranger and bookrunner, in a $235 million first lien credit facility provided to ATI Merger Sub, Inc., Avalign Holdings, Inc., and Avalign Technologies, Inc. in connection with Linden Capital Partners' acquisition of Avalign Technologies, Inc.
  • International pharmaceutical company builds anti-corruption compliance programJones Day has been retained by an international pharmaceutical company to conduct anti-corruption and anti-bribery risk assessments for over 35 countries.
  • Sanofi completes $2 billion bond issue in U.S. public offeringJones Day represented Sanofi, a global biopharmaceutical company, in its U.S. public offering of $2 billion of notes in two fixed rate tranches.
  • LeBaronBrown Industries acquires American International Chemical, Inc.Jones Day advised LeBaronBrown Industries LLC in connection with the acquisition and related financing of a majority interest in American International Chemical Inc., a leading specialty chemical and ingredients distributor based in Framingham, Massachusetts.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Smith & Nephew acquires Rotation Medical Inc. for up to $210 millionJones Day advised Smith & Nephew plc in its acquisition of Rotation Medical Inc., a developer of a novel tissue regeneration technology for shoulder rotator cuff repair, for an initial cash consideration of $125 million and up to $85 million over the next five years, contingent on financial performance.
  • The following represents experience acquired prior to joining Jones Day.

    Advised a Japanese life sciences company with its proposed acquisition of a U.S. contract manufacturing organization.

    Advised a U.S. health care system with its expansion of a unique, personalized medicine-based clinical research study to sites in the Middle East and Europe and advised on related U.S. IDE regulatory issues.

    Advised a U.S.-based biotech company with a multicountry analysis of statutory and ethical committee requirements to provide access to study a drug after completion of a clinical trial and assisted the company with development of clinical trial agreements, informed consent, and related regulatory issues in several South American jurisdictions.

    Advised a U.S.-based genetics company with laboratory testing agreements, data protection, and other regulatory issues in connection with genetics testing arrangements in the U.K. and Russia.

    Advised a U.S.-based biotech company with the development of informed consent and data privacy authorizations for use in the U.S., Australia, and multiple European jurisdictions.

    Assisted a Japanese life sciences company with several confidential buy- and sell-side transactions.

    Assisted a U.K.-based specialty pharmaceutical company in connection with the development of policies regarding the payment of health care professionals and anticorruption issues in Hong Kong, Taiwan, and Singapore and with the development of compliant centers of excellence product training programs in Hong Kong and Japan.

    Assisted a specialty patient recruitment firm with analysis of subject recruitment and advertising regulations in multiple ex-U.S. jurisdictions.

    Assisted a top three pharmaceutical company, on an outsourced basis, with the negotiation of more than 150 clinical trial agreements in nine South and Central American jurisdictions.

    Assisted a clinical data management provider in establishing a commercial agreement with a top three global pharmaceutical company, including providing legal analysis of pharmacovigilance transactions in a number of jurisdictions, including Japan, China, India, multiple EU jurisdictions, and the U.S.

    Drafted and negotiated pharmaceutical product distribution agreements on behalf of California-based company for Australia and New Zealand markets.

    Drafted and negotiated collaboration agreement between a top three pharmaceutical company and National Comprehensive Cancer Network regarding grant arrangements and a series of investigator-initiated trials in the oncology space.

    Speaking Engagements

    • October 5, 2017
      Belfast UK International Homecoming-Legal Symposium, "Marriage Equality and the Courts in the U.S."
    • November 9, 2016
      Jones Day Global Life Sciences Conference – 2016 Issues & Trends
    • October 21, 2016
      ABA Life Sciences Legal Summit
    • May 4, 2016
      Compliance in the Precision Medicine Era: Legal Considerations for the Contemporary Life Sciences Industry
    • March 7, 2016
      Boston Bar Association - Are You Ready? The Frontiers of Clinical Research and the Evolving Common Rule
    • December 2, 2015
      Boston Bar Association CLE - Medical Tourism: Legal Issues and Ethical Implications
    • October 23, 2015
      Treating the Medical Tourist: Issues for Healthcare Providers and Their Counsel, ABA Section of International Law 2015 Fall Meeting
    • October 21-22, 2015
      8th Annual Boston-Northwest Ireland Golden Bridges Giant Steps Conference - Honorary Co-Chair and Shark Tank Judge
    • October 2015
      The Legal and Ethical Implications of Medical Tourism, panel discussion
    • March 4, 2015
      Negotiating an Effective Clinical Trial Agreement and Limiting Litigation Exposure, ABA Life Sciences Legal Summit, Speaker
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.